THE DEMENTIA DISCOVERY FUND

The Dementia Discovery Fund Appoints Luca Santarelli, M.D., a Proven Neuroscience Leader, as the New Chair of its Scientific Advisory Board

Retrieved on: 
Wednesday, May 5, 2021
Santarelli

He has led drug programs in the areas of neuroscience, rare diseases, ophthalmology, metabolic and G.I., spanning the value chain from discovery research to commercialization.

Key Points: 
  • He has led drug programs in the areas of neuroscience, rare diseases, ophthalmology, metabolic and G.I., spanning the value chain from discovery research to commercialization.
  • Christian Jung, Partner at The Dementia Discovery Fund,said, "Dr. Santarelli brings scientific excellence, vast industry experience and a deep understanding of venture capital combined with a strong entrepreneurial spirit to our Scientific Advisory Board; we are delighted that he has agreed to become its Chair.
  • Luca Santarelli, said, "I am honored to be appointed Chair of DDF\'s world-class Scientific Advisory Board.
  • Learn more at www.TheDDFund.com\nSV Health Investors is a leading healthcare fund manager committed to investing in tomorrow\'s healthcare breakthroughs.

The Dementia Discovery Fund Appoints Luca Santarelli, M.D., a Proven Neuroscience Leader, as the New Chair of its Scientific Advisory Board

Retrieved on: 
Wednesday, May 5, 2021
Santarelli

He has led drug programs in the areas of neuroscience, rare diseases, ophthalmology, metabolic and G.I., spanning the value chain from discovery research to commercialization.

Key Points: 
  • He has led drug programs in the areas of neuroscience, rare diseases, ophthalmology, metabolic and G.I., spanning the value chain from discovery research to commercialization.
  • Christian Jung, Partner at The Dementia Discovery Fund,said, "Dr. Santarelli brings scientific excellence, vast industry experience and a deep understanding of venture capital combined with a strong entrepreneurial spirit to our Scientific Advisory Board; we are delighted that he has agreed to become its Chair.
  • Luca Santarelli, said, "I am honored to be appointed Chair of DDF\'s world-class Scientific Advisory Board.
  • Learn more at www.TheDDFund.com\nSV Health Investors is a leading healthcare fund manager committed to investing in tomorrow\'s healthcare breakthroughs.

The Dementia Discovery Fund Significantly Enhances its Neuroscience R&D Expertise to Support its Portfolio

Retrieved on: 
Wednesday, April 7, 2021
Cognitive disorders, Aging-associated diseases, Learning disabilities, Psychiatric diagnosis, Dementia, Psychiatry, Abnormal psychology, Mind

Dr. Jonathan Behr, Partner at The Dementia Discovery Fund,said, "We are delighted to welcome Lynne and Jim to DDF.

Key Points: 
  • Dr. Jonathan Behr, Partner at The Dementia Discovery Fund,said, "We are delighted to welcome Lynne and Jim to DDF.
  • Both are world-recognized experts in dementia and neuroscience R&D and their considerable expertise reinforces the key differentiation and value proposition of the DDF as we continue to invest in innovative dementia therapeutics and platform companies.
  • I look forward to working with my colleagues to help manage and expedite drug development to combat this dreadful disease."
  • The Dementia Discovery Fund (DDF) is a 250m specialist venture capital fund investing in, and creating, biotech companies pursuing transformational therapeutic approaches for dementias including Alzheimer's disease.

The Dementia Discovery Fund Significantly Enhances its Neuroscience R&D Expertise to Support its Portfolio

Retrieved on: 
Wednesday, April 7, 2021
Cognitive disorders, Aging-associated diseases, Learning disabilities, Psychiatric diagnosis, Dementia, Psychiatry, Abnormal psychology, Mind

Dr. Jonathan Behr, Partner at The Dementia Discovery Fund,said, "We are delighted to welcome Lynne and Jim to DDF.

Key Points: 
  • Dr. Jonathan Behr, Partner at The Dementia Discovery Fund,said, "We are delighted to welcome Lynne and Jim to DDF.
  • Both are world-recognized experts in dementia and neuroscience R&D and their considerable expertise reinforces the key differentiation and value proposition of the DDF as we continue to invest in innovative dementia therapeutics and platform companies.
  • I look forward to working with my colleagues to help manage and expedite drug development to combat this dreadful disease."
  • The Dementia Discovery Fund (DDF) is a 250m specialist venture capital fund investing in, and creating, biotech companies pursuing transformational therapeutic approaches for dementias including Alzheimer's disease.